Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.

Medicare will seek to negotiate lower list prices for the blockbuster diabetes and weight loss drugs Ozempic and Wegovy and 14 other medications, a cost-saving move that would take effect in 2027.

By Rebecca Robbins Medicare’s prices for the blockbuster weight-loss drugs Ozempic and Wegovy are likely to decline starting in 2027, thanks to their inclusion on a list of medicines whose ...

Nearly 2 in 3 people without diabetes quit popular weight loss drugs such as Ozempic or Victoza within one year, according to ...

Its weight-loss drug policy would fall to Trump's pick for health secretary, Robert F Kennedy Jr, and Mehmet Oz, Trump's ...

New poll shows about half of U.S. adults believe it is a good thing for adults to use weight-loss drugs if they are ...

Novo Nordisk's CEO is not worried about blockbuster semaglutide drugs being added to Medicare drug pricing negotiations this ...

The conversation surrounding health care reform has intensified in recent years, revealing deep divides in how we view personal responsibility, government intervention and public health ...

The Food and Drug Administration’s approval of Ozempic in 2021 for weight loss treatment ushered in a new era for the class ...